Fig. 2

Expression profile and integrated multiomics analysis in CD8 + T cells identified important signaling pathways in response to DAC treatment. a The expression fold changes of DEGs increased at different stages. Left panel: Expression of differentially expressed genes in the C1D0 period in anti-PD-1-vs. anti-PD-1/DAC-treated patients. Right panel: Expression of differentially expressed genes in the C2D0 period in anti-PD1-vs. anti-PD-1/DAC-treated patients. Red indicates up-regulated genes, and blue indicates down-regulated genes. b IPA pathway enrichment analysis. The input data are the DEGs in each period. The size of the circle shows the number of enriched genes in each pathway, and the depth of the color represents the P-value of enrichment. c Workflow of the experimental design and tSNE analysis of DMSs and DEGs in the C1D0 and C2D0 periods. Blue represents the combined therapy group with DAC and anti-PD-1, and red represents the monotherapy group with anti-PD-1. Upper panel: tSNE analysis of DMSs. Lower panel: tSNE analysis of DEGs. d Intersecting gene analysis of DMSs and DEGs. Orange represent DMSs, and blue represents DEGs. e IGV showed Runx3 methylation levels in different patients at different stages. f Correlation of gene expression and the promoter methylation level of Runx3. Upper panel: Violin diagram showing the statistical analysis of the difference in methylation levels in the Runx3 promoter region. The figure shows the median, upper quartile and lower quartile. Two-tailed unpaired t tests. Lower panel: The expression levels of Runx3 in different periods were analyzed by a line diagram. The x-axis represents the period, and the y-axis represents the FPKM value